|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype显示文摘AIM To evaluate the impact of the Glu167Lys(E167K) transmembrane 6 superfamily member 2(TM6SF2) variant on the biochemical and morphologic expression of liver lesions in human immunodeficiency virus(HIV)/hepatitis C virus(HCV) co-infected patients.METHODS The study comprised 167 consecutive patients with HIV/HCV coinfection and biopsy-proven chronic hepatitis. A pathologist graded liver fibrosis and necroinflammation using the Ishak scoring system, and steatosis using Kleiner's scoring system. Patients were genotyped for TM6SF2 E167K(rs58542926) by real-time Polymerase chain reaction. The 167 patients, 35 therapy-naive and 132 receiving ART, were prevalently males(73.6%), the median age was 40.7 years and the immunological condition good(median CD4+ cells/mm3 = 505.5).RESULTS The 17 patients with the TM6SF2 E167 K variant, compared with the 150 with TM6SF2-E/E, showed higher AST(P = 0.02) and alanine aminotransferase(P = 0.02) and higher fibrosis score(3.1 ± 2.0 vs 2.3 ± 1.5, P = 0.05). In a multivariate analysis, TM6SF2 E167 K was independently associated with severe fibrosis. The same analysis showed that HCV-genotype 3, present in 42.2% of patients was an independent predictor of severe steatosis. The association of TM6SF2 E167 K with severe steatosis, absent for the whole group of 167 patients, was re-evaluated separately for HCVgenotype 3 and non-3 patients: No factor was independently associated with severe steatosis in the HCV-genotype-3 subgroup, whereas an independent association was observed between severe steatosis and TM6SF2 E167 K in non-3 HCV genotypes. No association between the TM6SF2 E167 K variant and severe liver necroinflammation was observed.CONCLUSION In HIV/HCV coinfection the TM6SF2 E167 K variant is an independent predictor of severe fibrosis, but appears to be independently associated with severe steatosis only for patients with a non-3 HCV genotype. | Caterina Sagnelli Marco Merli Caterina Uberti-Foppa Hamid Hasson Anna Grandone Grazia Cirillo Stefania Salpietro Carmine Minichini Mario Starace Emanuela Messina Patrizia Morelli Emanuele Miraglia Del Giudice Adriano Lazzarin Nicola Coppola Evangelista Sagnelli | 2016 | World Journal of Gastroenterology2016，22，38： | 4 |
| 2 | Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients显示文摘 | Caterina Sagnelli Caterina Uberti-Foppa Laura Galli Giuseppe Pasquale Nicola Coppola Luca Albarello Carlo Doglioni Adriano Lazzarin Evangelista Sagnelli | 2013 | Brazilian Journal of Infectious Diseases2013，，： | 2 |
| 3 | The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years显示文摘 | Mark R Nelson Christine Katlama Julio S Montaner David A Cooper Brian Gazzard Bonaventura Clotet Adriano Lazzarin Knud Schewe Joep Lange Christina Wyatt Sue Curtis Shan-Shan Chen Stephen Smith Norbert Bischofberger James F Rooney | 2007 | AIDS2007，，10： | 2 |
| 4 | Liver Histology in HIV/Hepatitis C-Coinfected and HCV-Monoinfected Patients With Persistently Normal Alanine Aminotransferases显示文摘 | Caterina Sagnelli Caterina Uberti-Foppa Giuseppe Pasquale Nicola Coppola Luca Albarello Addolorata Masiello Carlo Doglioni Adriano Lazzarin Evangelista Sagnelli | 2010 | JAIDS Journal of Acquired Immune Deficiency Syndromes2010，，1： | 1 |
| 5 | POWER1和2试验中对曾治疗HIV-1感染患者给予地瑞那韦-利托那韦治疗48周时的疗效与安全性:2项随机试验资料的合并亚组分析显示文摘背景连续、随机、多国性POWER1和2ⅡB期研究旨在评价地瑞那韦(darunavir)联合应用小剂量利托那韦(ritonavir)对曾治疗HIV-1感染患者的疗效与安全性。本文作者进行了一项合并的亚组分析,对接受推荐剂量地瑞那韦-利托那韦的患者与接受其他蛋白酶抑制剂(PI)的患者进行比较,以提供治疗48周时有关疗效与安全性的最新信息。
方法在24周的剂量探索期和主要疗效分析后,被随机分入地瑞那韦-利托那韦组的患者继续服药600/100mg2次/d.而对照PI组的患者继续按指定治疗方案进入较长期的开放标记期;所有患者继续接受最佳背景治疗。对在分析时已达到第48周或提前停药的患者进行了评估;地瑞那韦~利托那韦组只纳入了从基线开始就服用600/100mg2次/d的患者。采用意向性治疗分析。POWER2研究(TMC114-C202)在ClinicalTrials.gov注册(NCT00071097)。结果48周时,110例地瑞那韦-利托那韦组患者中有67例(61%)病毒载量较基线下降≥1 log10拷贝/ml,而120例对照PI组患者中仅有18例(15%)(主要终点;反应率差值46%,95%CI35%~57%,P〈0,0001)。根据logisticS/归模型,该模型将分层因素(基线时原发PI突变数、恩夫韦地的使用、基线病毒载量)和研究作为协变量,反应率差值为50%(OR 11.72,95%CI 5.75~23.89)。在地瑞那韦-利托那韦组,如果校正治疗暴露,则不良事件率大都低于或近似于对照组。没有发现意外的安全事件。
结论采用地瑞那韦-利托那韦600/100mg 2次/d加最佳背景治疗的疗效反应大于对照PI。且疗效至少持续48周,尤其在曾治疗HIV患者中具有良好的安全性和耐受性。这一方案扩展了此类患者的治疗选择。 | Bonaventura Claret Nicholas Bellos Jean-Michel Molina David Cooper Jean-Christophe Goffard Adriano Lazzarin Andrej Wohrmann Christine Katlama Timothy Wilkin Richard Haubrich Calvin Cohen Charles Farthing Dushyantha Jayaweera Martin Markowitz Peter Ruane Sabrina Spinosa-Guzman Eric Lefebvre 王介明(译) 李宏建(译) | 2008 | 世界临床医学2008，2，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员